Document
IPR2015-01980, No. 1051 Exhibit - AMNEAL 1051 Tysabri Product Label 2008 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1051 Exhibit - AMNEAL 1051 Tysabri Product Label 2008 (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1043 Exhibit - AMNEAL 1043 Klauer and Zettl, Compliance, adherence and the treatment of multiple sclerosis (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1043 Exhibit - AMNEAL 1043 Klauer and Zettl, Compliance, adherence and the treatment of multiple sclerosis (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1044 Exhibit - AMNEAL 1044 Pelidou et al, Multiple sclerosis presented as clinically isolated syndrome the need for early diagnosis and treatment (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1044 Exhibit - AMNEAL 1044 Pelidou et al, Multiple sclerosis presented as clinically isolated syndrome the need for early diagnosis and treatment (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1027 Exhibit - AMNEAL 1027 Boissel and Nony, Using pharmacokinetic pharmacodynamic relationships to predict the effect of poor compliance (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1027 Exhibit - AMNEAL 1027 Boissel and Nony, Using pharmacokinetic pharmacodynamic relationships to predict the effect of poor compliance (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1025 Exhibit - AMNEAL 1025 Y Ge et al, Glatiramer acetate Copaxone treatment in relapsing remitting MS Quantitative MR assessment (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1025 Exhibit - AMNEAL 1025 Y Ge et al, Glatiramer acetate Copaxone treatment in relapsing remitting MS Quantitative MR assessment (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1018 Exhibit - AMNEAL 1018 KP Johnson, et al, Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1018 Exhibit - AMNEAL 1018 KP Johnson, et al, Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1056 Exhibit - AMNEAL 1056 US Patent Publication No 20090149541A1 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1056 Exhibit - AMNEAL 1056 US Patent Publication No 20090149541A1 (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1055 Exhibit - AMNEAL 1055 Stedmans Medical Dictionary for Health Professionals 2008 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1055 Exhibit - AMNEAL 1055 Stedmans Medical Dictionary for Health Professionals 2008 (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1031 Exhibit - AMNEAL 1031 Rich et al, Stepped care approach to treating MS A managed care treatment algorithm (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1031 Exhibit - AMNEAL 1031 Rich et al, Stepped care approach to treating MS A managed care treatment algorithm (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1049 Exhibit - AMNEAL 1049 Rebif US Product Label 2003 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1049 Exhibit - AMNEAL 1049 Rebif US Product Label 2003 (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1002 Exhibit - AMNEAL 1002 File History for US Patent No 8,399,413 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1002 Exhibit - AMNEAL 1002 File History for US Patent No 8,399,413 (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1033 Exhibit - AMNEAL 1033 Rohit Bakshi et al, Imaging of Multiple Sclerosis Role in Neurotherapeutics (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1033 Exhibit - AMNEAL 1033 Rohit Bakshi et al, Imaging of Multiple Sclerosis Role in Neurotherapeutics (P.T.A.B. Sep. 25, 2015)
+ More Snippets
Document
IPR2015-01980, No. 1010 Exhibit - AMNEAL 1010 Omar Khan et al, Randomized, prospective, rater blinded, four year, pilot study to compare the effect of daily versus every other day glatiramer...
Cite Document
IPR2015-01980, No. 1010 Exhibit - AMNEAL 1010 Omar Khan et al, Randomized, prospective, rater blinded, four year, pilot study to compare the effect of daily versus every other day glatiramer acetate 2
+ More Snippets
Document
IPR2015-01980, No. 1007 Exhibit - AMNEAL 1007 Affidavit of Marlene S Bobka dated December 9, 2014 and John J Jessop, Review and Evaluation of Pharmacology Toxicology Data Original ND...
Cite Document
IPR2015-01980, No. 1007 Exhibit - AMNEAL 1007 Affidavit of Marlene S Bobka dated December 9, 2014 and John J Jessop, Review and Evaluation of Pharmacology Toxicology Data Original NDA Review 1996 the
+ More Snippets
Document
IPR2015-01980, No. 1052 Exhibit - AMNEAL 1052 Copaxone US Product Label 2009 (P.T.A.B. Sep. 25, 2015)
Cite Document
IPR2015-01980, No. 1052 Exhibit - AMNEAL 1052 Copaxone US Product Label 2009 (P.T.A.B. Sep. 25, 2015)
+ More Snippets